Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Parkinson's disease
Kalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases
Pedersen, B. K., & Saltin, B. (2015) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/sms.12581 · Cited by 3,514
“The mean age of onset is around 60 years, although 5–10% of cases, classified as young onset, begin between the ages of 20 and 50 (de Lau & Breteler, 2006).”
Background
Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016
Dorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Epidemiology of Parkinson’s disease
Tysnes, O., & Storstein, A. M. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1686-y · Cited by 2,437
The epidemiology of Parkinson's disease: risk factors and prevention
Ascherio, A., & Schwarzschild, M. A. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30230-7 · Cited by 1,930
Enriched environments, experience-dependent plasticity and disorders of the nervous system
Nithianantharajah, J., & Hannan, A. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1970 · Cited by 1,771
Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors
Soldner, F., Hockemeyer, D. F., Beard, C., Gao, Q., Bell, G. W., Cook, E. G., Hargus, G., Blak, A. A., Cooper, O., Mitalipova, M. M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.02.013 · Cited by 1,584
The clinical symptoms of Parkinson's disease.
Sveinbjornsdottir, S. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13691 · Cited by 1,410
“The prevalence of PD in industrialised countries is generally estimated at 0.3% of the entire population and about 1% in people over 60 years of age (De Lau and Breteler 2006).”
BackgroundInfluential
MDS research criteria for prodromal Parkinson's disease
Berg, D., Postuma, R. B., Adler, C. H., Bloem, B. R., Chan, P., Dubois, B., Gasser, T., Goetz, C. G., Halliday, G. M., Joseph, L., et al. (2015) · Movement Disorders · doi:10.1002/mds.26431 · Cited by 1,394
100 years of Lewy pathology
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Clinical Neurology and Epidemiology of the Major Neurodegenerative DiseasesPreprint
Erkkinen, M. G., Kim, M., & Geschwind, M. D. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,231
“The incidence rate of PD is 8–18 individuals per 100,000 person-years (Tanner and Goldman 1996; Nussbaum and Ellis 2003; de Lau and Breteler 2006).”
Background
The role of JAK/STAT signaling pathway and its inhibitors in diseases.
Xin, P., Xu, X., Deng, C., Liu, S., Wang, Y., Zhou, X., Ma, H., Wei, D., & Sun, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106210 · Cited by 1,010
Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?
Reeve, A. K., Simcox, E. M., & Turnbull, D. M. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.01.004 · Cited by 1,013
The scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. D. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 947
Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease
Kehagia, A. A., Barker, R. A., & Robbins, T. W. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70212-x · Cited by 928
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Polyphenols and Human Health: Prevention of Disease and Mechanisms of Action
Vauzour, D., Rodriguez‐Mateos, A., Corona, G., Oruña-Concha, M. J., & Spencer, J. P. E. (2010) · Nutrients · doi:10.3390/nu2111106 · Cited by 885
“problem in our aging societies, primarily as there is an increased prevalence of both Alzheimer’s disease [174,175] and Parkinson’s disease [175-177] with age.”
Background
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801
Neuronal calcium signaling: function and dysfunction
Brini, M., Calí, T., Ottolini, D., & Carafoli, E. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1550-7 · Cited by 790
Collection and Analysis of a Parkinson Speech Dataset With Multiple Types of Sound Recordings
Şakar, B. E., Isenkul, M. E., Sakar, C. O., Sertbaş, A., Gürgen, F. S., Delil, Ş., Apaydın, H., & Kurşun, O. (2013) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2013.2245674 · Cited by 703
Probing and regulating dysfunctional circuits using deep brain stimulation
Lozano, A. M., & Lipsman, N. (2013) · Neuron · doi:10.1016/j.neuron.2013.01.020 · Cited by 665
Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases
Buendía, I., Michalska, P., Navarro, E., Gameiro‐Ros, I., Egea, J., & Leon, R. M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 698
Prevalence and incidence of Parkinson's disease in Europe
von Campenhausen, S., Bornschein, B., Wick, R., Bötzel, K., Sampaio, C., Poewe, W. H., Oertel, W. H., Siebert, U., Berger, K., & Dodel, R. C. (2005) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2005.04.007 · Cited by 624
What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease
Corti, O., Lesage, S., & Brice, A. (2011) · Physiological Reviews · doi:10.1152/physrev.00022.2010 · Cited by 652
Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 612
Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis.
DeMaagd, G. A., & Philip, A. (2015) · PubMed Central · Cited by 570
Invited Article: Nervous system pathology in sporadic Parkinson disease
Braak, H., & Tredici, K. D. (2008) · Neurology · doi:10.1212/01.wnl.0000312279.49272.9f · Cited by 548
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database
Lill, C. M., Roehr, J. T., McQueen, M. B., Kavvoura, F. K., Bagade, S., Schjeide, B. M., Schjeide, L. M., Meissner, E., Zauft, U., Allen, N. C., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002548 · Cited by 541
α-Synuclein misfolding and aggregation: Implications in Parkinson’s disease pathogenesis
Mehra, S., Sahay, S., & Maji, S. K. (2019) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2019.03.001 · Cited by 536
Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration
Masaldan, S., Bush, A. I., Devos, D., Rolland, A., & Moreau, C. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.09.033 · Cited by 494
“Most cases of PD are sporadic (90%) with several risk factors [45,67].”
Luteolin as an anti-inflammatory and neuroprotective agent: A brief review
Nabavi, S. F., Braidy, N., Gortzi, O., Sobarzo‐Sánchez, E., Daglia, M., Skalicka‐Woźniak, K., & Nabavi, S. M. (2015) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2015.09.002 · Cited by 484
“…the rapidly growing incidence of morbidity and mortality due to age-related diseases (Carranza, Carranza, Snyder, Shaw, Zesiewicz, & Snyde, 2013; de Lau & Breteler, 2006; Hendrie, 1998; Sosa-Ortiz, Acosta-Castillo, & Prince, 2012 Nabavi, Nabavi,Moghaddam, Naqinezhad, Bigdellou, Mohammadzadeh,…”
The role of microglia in retinal neurodegeneration: Alzheimer’s disease, parkinson, and glaucoma.
Ramirez, A. I., de Hoz, R., Salobrar-Garcia, E., Salazar, J. J., Rojas, B., Ajoy, D., López-Cuenca, I., Rojas, P., Triviño, A., & Ramírez, J. M. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00214 · Cited by 466
Advances in the genetics of Parkinson disease
Trinh, J., & Farrer, M. J. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.132 · Cited by 480
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Palfi, S., Gurruchaga, J. M., Ralph, G. S., Lepetit, H., Lavisse, S., Buttery, P. C., Watts, C., Miskin, J., Kelleher, M., Deeley, S., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61939-x · Cited by 484
An update on the diagnosis and treatment of Parkinson disease
Rizek, P., Kumar, N., & Jog, M. (2016) · Canadian Medical Association Journal · doi:10.1503/cmaj.151179 · Cited by 455
Determinants of dopaminergic neuron loss in Parkinson's disease
Surmeier, D. J. (2018) · FEBS Journal · doi:10.1111/febs.14607 · Cited by 483
Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease
Robak, L. A., Jansen, I. E., van Rooij, J., Uitterlinden, A. G., Kraaij, R., Jankovic, J., Heutink, P., Shulman, J. M., International Parkinson’s Disease Genomics Consortium (IPDGC), Nalls, M. A., et al. (2017) · Brain · doi:10.1093/brain/awx285 · Cited by 433
“The latter, more relaxed frequency threshold is based on the population prevalence (de Lau and Breteler, 2006; Pringsheim et al., 2014) and known incomplete penetrance of Parkinson’s disease risk alleles (Anheim et al., 2012; Rana et al., 2013; Trinh et al., 2014; Marder et al., 2015).”
Background
Variation in the miRNA-433 Binding Site of FGF20 Confers Risk for Parkinson Disease by Overexpression of α-Synuclein
Wang, G., van der Walt, J. M., Mayhew, G. M., Li, Y., Zuchner, S. L., Scott, W. K., Martin, E. R., & Vance, J. M. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.09.021 · Cited by 451
Recent Advances in the Genetics of Parkinson's Disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2011) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082410-101440 · Cited by 451
Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses
Bellou, V., Belbasis, L., Tzoulaki, I., Εvangelou, Ε., & Ioannidis, J. P. A. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.12.008 · Cited by 443
Structural changes of gut microbiota in Parkinson's disease and its correlation with clinical features
Li, W., Wu, X., Hu, X., Wang, T., Liang, S., Duan, Y., Jin, F., & Qin, B. (2017) · Science China Life Sciences · doi:10.1007/s11427-016-9001-4 · Cited by 406
Clinical Approach to Parkinson's Disease: Features, Diagnosis, and Principles of ManagementPreprint
Massano, J., & Bhatia, K. P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008870 · Cited by 449
“Annual incidence rates range from 8.6 to 19 per 100,000 (Twelves et al. 2003; de Lau and Breteler 2006; Alves et al. 2008).”
BackgroundInfluential
The retina in Parkinson's disease
Archibald, N. K., Clarke, M. W., Mosimann, U. P., & Burn, D. J. (2009) · Brain · doi:10.1093/brain/awp068 · Cited by 408
N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease
Olivares, D., K. Deshpande, V., Shi, Y., K. Lahiri, D., H. Greig, N., T. Rogers, J., & Huang, X. (2012) · Current Alzheimer Research · doi:10.2174/156720512801322564 · Cited by 407
Review: Sporadic Parkinson's disease: development and distribution ofα‐synuclein pathology
Tredici, K. D., & Braak, H. (2015) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12298 · Cited by 416
Microglia and astrocyte dysfunction in parkinson's disease
Kam, T., Hinkle, J. T., Dawson, T. M., & Dawson, V. L. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105028 · Cited by 420
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives
Schapira, A. H. V., Olanow, C. W., Greenamyre, J. T., & Bézard, E. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61010-2 · Cited by 399
Parkinson's disease: Autoimmunity and neuroinflammation
VIRGILIO, A. D., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Appiani, M. C., & VINCENTIIS, M. D. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.022 · Cited by 397
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
The Role of Magnesium in Neurological Disorders
Kirkland, A. E., Sarlo, G. L., & Holton, K. F. (2018) · Nutrients · doi:10.3390/nu10060730 · Cited by 382
“Other factors that impact PD include mitochondrial dysfunction, oxidative stress, and protein dysfunction [143].”
Background
The Hsp70/Hsp90 Chaperone Machinery in Neurodegenerative Diseases
Lackie, R. E., Maciejewski, A., Ostapchenko, V. G., Marques-Lopes, J., Choy, W., Duennwald, M. L., Prado, V. F., & Prado, M. A. M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00254 · Cited by 390
Evaluation of handwriting kinematics and pressure for differential diagnosis of Parkinson's disease
Drotár, P., Mekyska, J., Rektorová, I., Masárová, L., Smékal, Z., & Faúndez-Zanuy, M. (2016) · Artificial Intelligence in Medicine · doi:10.1016/j.artmed.2016.01.004 · Cited by 375
Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
Magrinelli, F., Picelli, A., Tocco, P., Federico, A., Roncari, L., Smania, N., Zanette, G., & Tamburin, S. (2016) · Parkinson s Disease · doi:10.1155/2016/9832839 · Cited by 373
Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.
Nilsson, K., Bennich, H., Johansson, S. G. O., & Pontén, J. (1970) · PubMed Central · Cited by 368
Epidemiology of Parkinson Disease
Lee, A., & Gilbert, R. (2016) · Neurologic Clinics · doi:10.1016/j.ncl.2016.06.012 · Cited by 405
New insights into the complex role of mitochondria in Parkinson’s disease
Grünewald, A., Kumar, K. R., & Sue, C. M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.09.003 · Cited by 375
Age at onset and Parkinson disease phenotype
Pagano, G., Ferrara, N., Brooks, D. J., & Pavese, N. (2016) · Neurology · doi:10.1212/wnl.0000000000002461 · Cited by 360
Genetics of Parkinson's disease
Lill, C. M. (2016) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2016.11.001 · Cited by 387
Neurodegenerative and neurological disorders by small inhaled particles
Heusinkveld, H. J., Wahle, T., Campbell, A., Westerink, R. H. S., Tran, L., Johnston, H., Stone, V., Cassee, F. R., & Schins, R. P. F. (2016) · NeuroToxicology · doi:10.1016/j.neuro.2016.07.007 · Cited by 331
“About 40% of people over the age of 85 suffer from AD and another 10% from Parkinson ’ s disease (PD) (de Lau and Breteler, 2006; Ferri et al., 2005).”
Trial of Cinpanemab in Early Parkinson’s Disease
Lang, A. E., Siderowf, A. D., Macklin, E. A., Poewe, W. H., Brooks, D. J., Fernandez, H. H., Rascol, O., Giladi, N., Stocchi, F., Tanner, C. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203395 · Cited by 362
Incidence of Parkinson disease in North America
Willis, A. W., Roberts, E., Beck, J. C., Fiske, B., Ross, W., Savica, R., Van Den Eeden, S. K., Tanner, C. M., Marras, C., on behalf of the Parkinson’s Foundation P4 Group, et al. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00410-y · Cited by 341
Brain tyrosinase overexpression implicates age-dependent neuromelanin production in Parkinson’s disease pathogenesis
Carballo‐Carbajal, I., Laguna, A., Romero‐Giménez, J., Cuadros, T., Bové, J., Martínez‐Vicente, M., Parent, A., González-Sepúlveda, M., Peñuelas, N., Torra, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08858-y · Cited by 360
Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve
Uemura, N., Yagi, H., Uemura, M. T., Hatanaka, Y., Yamakado, H., & Takahashi, R. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0257-5 · Cited by 328
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 337
The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson's Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T
Schwarz, S. T., Afzal, M., Morgan, P. S., Bajaj, N. P. S., Gowland, P. A., & Auer, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093814 · Cited by 344
Automated analysis of connected speech reveals early biomarkers of Parkinson’s disease in patients with rapid eye movement sleep behaviour disorder
Hlavnička, J., Čmejla, R., Tykalová, T., Šonka, K., Růžička, E., & Rusz, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-00047-5 · Cited by 326
Mortality in Parkinson's disease: A systematic review and meta‐analysis
Macleod, A. D., Taylor, K. S. M., & Counsell, C. E. (2014) · Movement Disorders · doi:10.1002/mds.25898 · Cited by 328
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D. S., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 340
Recent Advances in Wearable Sensors for Health Monitoring
Rodgers, M. M., Pai, V. M., & Conroy, R. S. (2015) · IEEE Sensors Journal · doi:10.1109/jsen.2014.2357257 · Cited by 325
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311
CpG Demethylation Enhances Alpha-Synuclein Expression and Affects the Pathogenesis of Parkinson's Disease
Matsumoto, L., Takuma, H., Tamaoka, A., Kurisaki, H., Date, H., Tsuji, S., & Iwata, A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015522 · Cited by 309
The role of histone modifications: from neurodevelopment to neurodiseases
Park, J., Lee, K., Kim, K., & Yi, S.-J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01078-9 · Cited by 333
Associated factors for REM sleep behavior disorder in Parkinson disease
Sixel‐Döring, F., Trautmann, E., Mollenhauer, B., & Trenkwalder, C. (2011) · Neurology · doi:10.1212/wnl.0b013e31822e560e · Cited by 307
The Brainstem Pathologies of Parkinson's Disease and Dementia with Lewy Bodies
Seidel, K., Mahlke, J., Siswanto, S., Krüger, R., Heinsen, H., Auburger, G. W. J., Bouzrou, M., Grinberg, L. T., Wicht, H., Korf, H., et al. (2014) · Brain Pathology · doi:10.1111/bpa.12168 · Cited by 301
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
“For Parkinson’s dementia, age (Pringsheim et al. 2014), male sex (de Lau and Breteler 2006), a history of anxiety or depression and environmental factors such as pesticide exposure, head injury and rural living (Noyce et al. 2012) are among suggested risk factors.”
Background
The Therapeutic Potential of Metformin in Neurodegenerative Diseases
Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00400 · Cited by 316
Temporal trends in the prevalence of Parkinson's disease from 1980 to 2023: a systematic review and meta-analysis
Zhu, J., Cui, Y., Zhang, J., Yan, R., Su, D., Zhao, D. B., Wang, A., & Feng, T. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00094-1 · Cited by 318
Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease
Taylor, J. M., Main, B. S., & Crack, P. J. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.016 · Cited by 313
Adult Neurogenesis in Neurodegenerative Diseases: Figure 1.Preprint
Winner, B., & Winkler, J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a021287 · Cited by 323
“PD is the most common movement disorder with an increasing prevalence because of an aging population (de Lau and Breteler 2006).”
Background
Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature
Ramesh, S., & Arachchige, A. S. P. M. (2023) · AIMS neuroscience · doi:10.3934/neuroscience.2023017 · Cited by 353
Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease
Mudò, G., Mäkelä, J., Liberto, V. D., Tselykh, T. V., Olivieri, M., Piepponen, P. T., Eriksson, O., Mälkiä, A., Bonomo, A., Kairisalo, M., et al. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0850-z · Cited by 305
The hallmarks of P arkinson's disease
Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · FEBS Journal · doi:10.1111/febs.12335 · Cited by 317
Caffeine for treatment of Parkinson disease
Postuma, R. B., Lang, A. E., Munhoz, R. P., Charland, K., Pelletier, A., Moscovich, M., Filla, L., Zanatta, D., Romenets, S. R., Altman, R., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e318263570d · Cited by 311
Translation Initiator EIF4G1 Mutations in Familial Parkinson Disease
Chartier‐Harlin, M., Dächsel, J. C., Vilariño‐Güell, C., Lincoln, S., Leprêtre, F., Hulihan, M., Kachergus, J. M., Milnerwood, A. J., Tapia, L., Song, M.-S., et al. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.08.009 · Cited by 316
The influence of microglia on the pathogenesis of Parkinson's disease
Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 302
Meta-analysis of Parkinson disease: Identification of a novel locus, RIT2
Pankratz, N., Beecham, G., Destefano, A., Dawson, T. M., Doheny, K., Factor, S., Hamza, T., Hung, A. Y., Hyman, B., Ivinson, A., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22687 · Cited by 309
The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer’s Disease and Other Neurodegenerative Disorders
Czubowicz, K., Jęśko, H. M., Wencel, P. L., Lukiw, W. J., & Strosznajder, R. P. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1448-3 · Cited by 303
Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease
Whone, A., Luz, M., Boca, M., Woolley, M., Mooney, L., Dharia, S., Broadfoot, J., Cronin, D., Schroers, C., Barua, N. U., et al. (2019) · Brain · doi:10.1093/brain/awz023 · Cited by 282
Trehalose ameliorates dopaminergic and tau pathology in parkin deleted/tau overexpressing mice through autophagy activation
Rodríguez-Navarro, J. A., Rodríguez, L., Casarejos, M. J., Solano, R. M., Gómez, A., Perucho, J., Cuervo, A. M., García de Yébenes, J., & Mena, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.014 · Cited by 298
The genetic background of Parkinson's disease: current progress and future prospects
Kalinderi, K., Bostantjopoulou, S., & Fidani, L. (2016) · Acta Neurologica Scandinavica · doi:10.1111/ane.12563 · Cited by 304
A Senescence-Centric View of Aging: Implications for Longevity and Disease
Borghesan, M., Hoogaars, W. M. H., Varela-Eirin, M., Talma, N., & Demaria, M. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.07.002 · Cited by 267
“The prevalence of Parkinson’s disease (PD), the secondmost common neurodegenerative disorder, increases with advanced age [88].”
Background
Discovery of Vinyl Sulfones as a Novel Class of Neuroprotective Agents toward Parkinson’s Disease Therapy
Woo, S. Y., Kim, J. H., Moon, M. K., Han, S. H., Yeon, S. K., Choi, J., Jang, B. K., Song, H. J., Kang, Y. G., Kim, J. W., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401788m · Cited by 270
Characterization of PINK1 processing, stability, and subcellular localization
Lin, W., & Kang, U. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05398.x · Cited by 269
Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease
Postuma, R. B., Gagnon, J., Vendette, M., & Montplaisir, J. Y. (2009) · Brain · doi:10.1093/brain/awp244 · Cited by 261
An efficient hybrid kernel extreme learning machine approach for early diagnosis of Parkinson׳s disease
Chen, H., Wang, G., Ma, C., Cai, Z., Liu, W., & Wang, S. (2015) · Neurocomputing · doi:10.1016/j.neucom.2015.07.138 · Cited by 256
Norepinephrine: The redheaded stepchild of Parkinson's disease
Rommelfanger, K. S., & Weinshenker, D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.036 · Cited by 261
Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration
Ma, X., Hao, J., Wu, J., Li, Y., Cai, X., & Zheng, Y. (2022) · Advanced Materials · doi:10.1002/adma.202106723 · Cited by 257
The economic impact of Parkinson's disease
Findley, L. J. J. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.06.003 · Cited by 249
“3% [3].”
Genetic risk factors in Parkinson’s disease
Billingsley, K. J., Bandrés‐Ciga, S., Sáez-Atiénzar, S., & Singleton, A. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2817-y · Cited by 262
“…are no available treatments that can stop or reverse the neurodegenerative process in PD. PD shows an age-dependent prevalence in which about 1% of the global population at 65 years of age and over and about 4–5% of individuals at 85 years of age and over are affected (de Lau and Breteler 2006).”
Background
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks